JADE MONO-2 Study Results: Efficacy and Safety of Abrocitinib in Patients With Moderate to Severe Atopic Dermatitis

From the 2020 Annual Meetings of the American Academy of Allergy, Asthma, and Immunology (AAAAI), the American Academy of Dermatology (AAD), and Revolutionizing Atopic Dermatitis (RAD).
Moderate to severe atopic dermatitis was significantly improved for adolescents and adults treated with abrocitinib vs placebo.
Format: Microsoft PowerPoint (.ppt)
File Size: 210 KB
Released: July 20, 2020

Acknowledgements

Provided by Clinical Care Options.

Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA

Sophia Kelley
(203)-316-2125
skelley@clinicaloptions.com
www.clinicaloptions.com

This educational activity is supported by educational grants from
AbbVie
Pfizer Inc.

Related Content

Results from subgroup analysis analyzing the efficacy, safety of dupilumab with or without concomitant TCS in patients with erythrodermic AD, from CCO

Released: July 27, 2020

Effect of withdrawal and retreatment with upadacitinib during an interim analysis of the 88-week phase 2b trial, from CCO

Released: July 27, 2020

Efficacy, safety of baricitinib in patients with 1 or more atopic comorbidity at baseline in BREEZE-AD1 and BREEZE-AD2, from CCO

Released: July 27, 2020

An investigation of the efficacy and safety of dupilumab and concomitant topical corticosteroids in children aged ≥ 6 to < 12 years with severe AD: atopic dermatitis conference coverage from CCO

Released: July 20, 2020

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Welcome to the CCO site.

You are accessing CCO's educational content today as a Guest user.

If you would like to continue with free, full access to the CCO Web sites, including free CME/CE credits, please click the button below.

Continue

More info

CCO’s educational programs are available completely free of charge on the ClinicalOptions.com, inPractice.com, and inPracticeAfrica.com Web sites. Certain features and functions are restricted for Guest users. By consenting to become a full member, you are eligible to receive CME/CE credit or participation certificates from certified activities, to register for CCO’s free live meetings and webinars, and to receive CCO’s email newsletters alerting you to new content. You can unsubscribe from our emails at any time. CCO strictly protects the privacy of our members, according to our privacy policy.

A confirmation email will be sent to . Not You?